Oncogene mutation profile predicts tumor regression and survival in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy and radical surgery
Tumor response to preoperative chemoradiotherapy and postoperative survival differs among patients with locally advanced rectal cancer. The objective was to find correlations of mutated oncogenes and clinical outcomes in locally advanced rectal cancer. A total of 70 patients with preoperative preope...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
IOS Press
2017-06-01
|
Series: | Tumor Biology |
Online Access: | https://doi.org/10.1177/1010428317709638 |
id |
doaj-6014216ac3c9424dabf2e39ad40c0423 |
---|---|
record_format |
Article |
spelling |
doaj-6014216ac3c9424dabf2e39ad40c04232021-05-02T23:10:23ZengIOS PressTumor Biology1423-03802017-06-013910.1177/1010428317709638Oncogene mutation profile predicts tumor regression and survival in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy and radical surgeryJianhong Peng0Junzhong Lin1Miaozhen Qiu2Yujie Zhao3Yuxiang Deng4Jianyong Shao5Peirong Ding6Huizhong Zhang7Desen Wan8Zhenhai Lu9Zhizhong Pan10Department of Colorectal Surgery, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine, Guangzhou, ChinaDepartment of Colorectal Surgery, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine, Guangzhou, ChinaDepartment of Medical Oncology, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine, Guangzhou, ChinaDepartment of Colorectal Surgery, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine, Guangzhou, ChinaDepartment of Colorectal Surgery, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine, Guangzhou, ChinaDepartment of Molecular Diagnostics, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine, Guangzhou, ChinaDepartment of Colorectal Surgery, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine, Guangzhou, ChinaDepartment of Pathology, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine, Guangzhou, ChinaDepartment of Colorectal Surgery, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine, Guangzhou, ChinaDepartment of Colorectal Surgery, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine, Guangzhou, ChinaDepartment of Colorectal Surgery, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine, Guangzhou, ChinaTumor response to preoperative chemoradiotherapy and postoperative survival differs among patients with locally advanced rectal cancer. The objective was to find correlations of mutated oncogenes and clinical outcomes in locally advanced rectal cancer. A total of 70 patients with preoperative preoperative chemoradiotherapy followed by radical surgery at a single cancer center between 2006 and 2012 were enrolled. Pretreatment tumor biopsy samples were assayed for 238 mutation hotspots harboring 19 oncogenes by time-of-flight mass spectrometry and OncoCarta Array. Oncogene mutations were found in 48.6% of patients (34/70). KRAS was the most frequent driver mutation, found in 35.7% of patients (25/70), followed by PIK3CA (14.3%), NRAS (5.7%), FLT3 (2.9%), and BRAF (1.4%). Multiple gene mutations were observed in eight patients (11.4%). Tumors with KRAS mutations responded poorly to preoperative chemoradiotherapy (p = 0.044). Patients with oncogene mutations had worse 3-year disease-free survival than those without mutations (67.2% vs 94.2%, p = 0.010). Patients with KRAS or RAS mutations had lower 3-year disease-free survival (68% vs 88.3%, p = 0.016; 65.5% vs 92.3%, p = 0.004, respectively) and 3-year overall survival (88% vs 95.4%, p = 0.020; 89.7% vs 94.9%, p = 0.036, respectively) than those without KRAS or RAS mutations. Oncogene mutation status affected tumor response to treatment and long-term survival in locally advanced rectal cancer.https://doi.org/10.1177/1010428317709638 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jianhong Peng Junzhong Lin Miaozhen Qiu Yujie Zhao Yuxiang Deng Jianyong Shao Peirong Ding Huizhong Zhang Desen Wan Zhenhai Lu Zhizhong Pan |
spellingShingle |
Jianhong Peng Junzhong Lin Miaozhen Qiu Yujie Zhao Yuxiang Deng Jianyong Shao Peirong Ding Huizhong Zhang Desen Wan Zhenhai Lu Zhizhong Pan Oncogene mutation profile predicts tumor regression and survival in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy and radical surgery Tumor Biology |
author_facet |
Jianhong Peng Junzhong Lin Miaozhen Qiu Yujie Zhao Yuxiang Deng Jianyong Shao Peirong Ding Huizhong Zhang Desen Wan Zhenhai Lu Zhizhong Pan |
author_sort |
Jianhong Peng |
title |
Oncogene mutation profile predicts tumor regression and survival in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy and radical surgery |
title_short |
Oncogene mutation profile predicts tumor regression and survival in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy and radical surgery |
title_full |
Oncogene mutation profile predicts tumor regression and survival in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy and radical surgery |
title_fullStr |
Oncogene mutation profile predicts tumor regression and survival in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy and radical surgery |
title_full_unstemmed |
Oncogene mutation profile predicts tumor regression and survival in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy and radical surgery |
title_sort |
oncogene mutation profile predicts tumor regression and survival in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy and radical surgery |
publisher |
IOS Press |
series |
Tumor Biology |
issn |
1423-0380 |
publishDate |
2017-06-01 |
description |
Tumor response to preoperative chemoradiotherapy and postoperative survival differs among patients with locally advanced rectal cancer. The objective was to find correlations of mutated oncogenes and clinical outcomes in locally advanced rectal cancer. A total of 70 patients with preoperative preoperative chemoradiotherapy followed by radical surgery at a single cancer center between 2006 and 2012 were enrolled. Pretreatment tumor biopsy samples were assayed for 238 mutation hotspots harboring 19 oncogenes by time-of-flight mass spectrometry and OncoCarta Array. Oncogene mutations were found in 48.6% of patients (34/70). KRAS was the most frequent driver mutation, found in 35.7% of patients (25/70), followed by PIK3CA (14.3%), NRAS (5.7%), FLT3 (2.9%), and BRAF (1.4%). Multiple gene mutations were observed in eight patients (11.4%). Tumors with KRAS mutations responded poorly to preoperative chemoradiotherapy (p = 0.044). Patients with oncogene mutations had worse 3-year disease-free survival than those without mutations (67.2% vs 94.2%, p = 0.010). Patients with KRAS or RAS mutations had lower 3-year disease-free survival (68% vs 88.3%, p = 0.016; 65.5% vs 92.3%, p = 0.004, respectively) and 3-year overall survival (88% vs 95.4%, p = 0.020; 89.7% vs 94.9%, p = 0.036, respectively) than those without KRAS or RAS mutations. Oncogene mutation status affected tumor response to treatment and long-term survival in locally advanced rectal cancer. |
url |
https://doi.org/10.1177/1010428317709638 |
work_keys_str_mv |
AT jianhongpeng oncogenemutationprofilepredictstumorregressionandsurvivalinlocallyadvancedrectalcancerpatientstreatedwithpreoperativechemoradiotherapyandradicalsurgery AT junzhonglin oncogenemutationprofilepredictstumorregressionandsurvivalinlocallyadvancedrectalcancerpatientstreatedwithpreoperativechemoradiotherapyandradicalsurgery AT miaozhenqiu oncogenemutationprofilepredictstumorregressionandsurvivalinlocallyadvancedrectalcancerpatientstreatedwithpreoperativechemoradiotherapyandradicalsurgery AT yujiezhao oncogenemutationprofilepredictstumorregressionandsurvivalinlocallyadvancedrectalcancerpatientstreatedwithpreoperativechemoradiotherapyandradicalsurgery AT yuxiangdeng oncogenemutationprofilepredictstumorregressionandsurvivalinlocallyadvancedrectalcancerpatientstreatedwithpreoperativechemoradiotherapyandradicalsurgery AT jianyongshao oncogenemutationprofilepredictstumorregressionandsurvivalinlocallyadvancedrectalcancerpatientstreatedwithpreoperativechemoradiotherapyandradicalsurgery AT peirongding oncogenemutationprofilepredictstumorregressionandsurvivalinlocallyadvancedrectalcancerpatientstreatedwithpreoperativechemoradiotherapyandradicalsurgery AT huizhongzhang oncogenemutationprofilepredictstumorregressionandsurvivalinlocallyadvancedrectalcancerpatientstreatedwithpreoperativechemoradiotherapyandradicalsurgery AT desenwan oncogenemutationprofilepredictstumorregressionandsurvivalinlocallyadvancedrectalcancerpatientstreatedwithpreoperativechemoradiotherapyandradicalsurgery AT zhenhailu oncogenemutationprofilepredictstumorregressionandsurvivalinlocallyadvancedrectalcancerpatientstreatedwithpreoperativechemoradiotherapyandradicalsurgery AT zhizhongpan oncogenemutationprofilepredictstumorregressionandsurvivalinlocallyadvancedrectalcancerpatientstreatedwithpreoperativechemoradiotherapyandradicalsurgery |
_version_ |
1721486697081864192 |